Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor

Ann N Y Acad Sci. 1991;640:272-5. doi: 10.1111/j.1749-6632.1991.tb00232.x.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Animals
  • Carbamates / metabolism
  • Carbamates / therapeutic use*
  • Cholinesterase Inhibitors / metabolism
  • Cholinesterase Inhibitors / therapeutic use*
  • Humans
  • Male
  • Phenylcarbamates*
  • Physostigmine / metabolism
  • Physostigmine / therapeutic use
  • Placebos
  • Rats
  • Rivastigmine

Substances

  • Carbamates
  • Cholinesterase Inhibitors
  • Phenylcarbamates
  • Placebos
  • Physostigmine
  • Rivastigmine